Análisis del Proceso de Actualización de Medicamentos en el Cuadro Básico y Catálogo de Insumos del Sector Salud

Abstract

The strengthening of the process was conducted with methodological rigor based on critical analysis of scientific evidence, with transparency and legitimacy under a legal framework to promote resource optimization. The highest percentage of requests was for drugs which are the most commonly used therapeutic technology; for this reason it requires a proper selection process to ensure greater health benefit that ensures efficient use of economic resources. The economic evaluation was a support tool to consider in addition to price, the value of health determined by the quality of evidence, establishing a GDP per capita as a threshold to define a drug as an efficient alternative.

Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico

“…All future costs and health benefits (i.e., life-years, QALYs) were discounted at 5% per Centro Nacional de Excelencia Tecnológica en Salud guidelines [56]. In this analysis, cost-effectiveness was assessed using the WTP thresholds of 1 times GDP per capita (i.e., MXP 141,200/QALY) and 3 times GDP per capita (i.e., MXP 423,600/QALY) suggested by the Mexican government and the World Health Organization [57]. Note that an ICER below the more conservative threshold of 1 times GDP per QALY is considered to be very cost-effective per the World Health Organization.…”

“…Mexico's independent health technology assessment body, Centro Nacional de Excelencia Tecnológica en Salud, encourages the use of cost-effectiveness analysis and states a willingness-to-pay (WTP) threshold of 1 times the gross domestic product (GDP) per capita as "very cost-effective" (MXP 141,120 or US $10,500; exchange rate as of September 26, 2014 of US $1 ¼ MXP 13.44) [31]. Centro Nacional de Excelencia Tecnológica en Salud further states that for treatments with costs per QALY gained of ≥1 and ≤3 times the GDP per capita, a detailed analysis should be performed; those with costs per QALY gained of >3 times the GDP per capita should not be considered "cost-effective" [32,33]. These WTP thresholds are in line with those recommended by the World Health Organization [34].…”